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Summary: In this paper we present a new method for optimizing designs of experiments for non-linear mixed
effects models, where a categorical factor with covariate information is a design variable combined with another
design factor. The work is motivated by the need to efficiently design pre-clinical experiments in enzyme kinetics for a
set of Human Liver Microsomes. However, the results are general and can be applied to other experimental situations
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where the variation in the response due to a categorical factor can be partially accounted for by a covariate. The
covariate included in the model explains some systematic variability in a random model parameter. This approach
allows better understanding of the population variation as well as estimation of the model parameters with higher
precision.
Key words: Covariates; Enzyme kinetics; Planning experiments; Random model parameters.
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1. Introduction
Nonlinear mixed effects models have been extensively used in various applications, in par-
ticular in evaluation of the population pharmacokinetic and pharmacodynamic parameters
in drug development studies, see for example Chapter 5 of Fitzmaurice et al. (2009). It has
been shown that design optimization in the mixed models approach can reduce the number of
observations per individual and at the same time provide good predictions of the individual
responses as well as good estimates of the population parameters including their variances.
This is particularly important in studies in which many observations per individual are not
feasible, for example when the patients are small children. Further improvements are possible
by including covariates which are partially responsible for the inter-individual variability of
the observed responses.
There has been some work done on covariate selection in non-linear mixed effects model
building. Wu and Wu (2002) consider such a method in application to HIV data (viral decay
rate), which are usually very sparse for individuals, although the number of individuals
and the inter-individual variation may be large. There is also a large number of covariates
available but only some of them are related to the base model parameters and account for
inter-individual variation in the measured viral decay rate. The authors compared various
methods of choosing a model given the data when there are missing covariate values. There is
however an important open question of how to choose the experimental variables so that the
observed responses (data) are most informative. The main design variable in this instance is
the time of measuring decay rate, but then the question is which individuals, that is which
covariate values, will give best information for efficient model building and evaluation.
Ding and Wu (2001) added an indicator variable as a covariate in their mixed effects model
of viral decay for antiviral drugs in HIV to represent a treatment. The model parameters
depend on the covariate. They compared type I errors for various tests for the hypothesis of
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equality of the treatment effects. In Wu and Ding (2002) they examined the effect of various
sampling times on the power for identifying a treatment difference. Retout et al. (2007)
showed the efficiency of D-optimum designs for the Wald test of such differences. However,
they did not consider the choice of covariate values in the design optimization.
Denti et al. (2010) showed that relating the model parameters to a selection of covariates
can decrease significantly the inter-subject variability due to random individual effects. A
part of the population variability can be explained by the covariates. They also pointed out
that this can lead to savings in the numbers of individual observations and so to increasing the
efficiency of the experiments. They also noted the potential of including covariate information
at the design stage. We are not aware, however, that this has been done in the kind of
experimental set up considered in this paper.
Interest in the optimum design of experiments for mixed effects models has increased over
recent decades. Various software packages, such as PFIM, PopED, PopDes or POPT, which
provide optimum designs for blood sampling times in pharmacokinetic and pharmacody-
namic models are now available and a comparison of the software is presented in Nyberg et
al. (2014). Although the models allow for covariates, the design domain defined there does
not allow for direct application of the software to our problem, since we do not have a free
choice of covariate values. In our optimisation problem we choose the optimum replication
of each of a set of experimental units which carry specific values of the covariates.
Our work was initially motivated by applications in pre-clinical studies of evaluating poten-
tial drug-drug interactions. The in-vitro experiments are done in Human Liver Microsomes
(HLMs) as it is in the liver that most of the enzymes responsible for metabolism occur. These
are Cytochrome P450 enzymes (CYPs) and they can be partly responsible for the inter-HLM
(inter-subject) variability in respect of the drug metabolism, cf. Hasler et al. (1999).
Belle et al. (2000) showed that population analysis of sparse data can reduce coefficients
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of variation of some parameters in enzyme kinetic models. In experiments with HLMs they
expressed the inter-HLM variability in terms of the parameter Vmax of a two-enzyme kinetic
model. They also found that the variability in this parameter was related to activity of
CYP1A2. Including the activity as a covariate into the model reduced the coefficient of
variation (CV) of the parameter estimator from 70% to 39% and it also reduced slightly the
error variance estimator’s CV (intra-HLM variability). Belle et al. (2000) do not however
consider optimum planning of the experiment.
In this study we investigated CYP2B6, which is a member of the cytochrome P450 su-
perfamily of enzymes, which are responsible for the catalysis of many reactions involved in
drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes
to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme
is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide
and ifosphamide. However, in the context of the data presented herein we investigated the
metabolism by CYP2B6 of a selective prototypical substrate bupropion.
In this paper we present a method of planning experiments where covariates are treated
as design variables whose values are chosen, from the set of values in the available subjects,
by the experimenter in combination with other treatment factors. In Section 2 we present
notation for a general model and a population design, as well as a design optimality cri-
terion. We also derive the model approximation and the information matrix form. Section
3 is devoted to the application in enzyme kinetics, where we briefly present the numerical
optimization algorithm. We also show how the criterion of optimality can be extended to
allow for a model transformation in case the residuals do not follow the model assumptions
and we present the results. Finally we comment on our findings and in Section 4 we give
brief conclusions.
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2. Theory and methods
2.1 Modelling
We denote by x a vector of levels of a treatment factor, continuous or discrete, although in
regression models they are usually continuous, such as concentration of a drug injected into
blood plasma, time of taking measurements or temperature at which a chemical reaction
is run. We also assume that the population under investigation is diverse in its nature
and the diversity can be partially explained by some concomitant variables (covariates) of
the population members. These, for example, could be the size of a tumor, its grade and
the number of affected lymph nodes of cancer patients taking part in a clinical trial or
enzyme activity in drug metabolism in preclinical studies. We denote by z a vector of such
covariates. If the purpose of the experiment is to estimate and make inferences on some
treatment parameters, then the following question arises: are some values of the covariates
more informative than others and, if so, what combinations of individuals with the values of
the treatment factors should be used? In Section 3 we show that we can improve the efficiency
of estimation of Michaelis-Menten model parameters by an optimum selection of liver tissue
preparations characterized by enzymes’ activities combined with levels of concentration of
the drug under investigation.
We denote by Is a set of available elements of the population S, that is, Is = {1, 2, . . . , s}
and by I(n) any subset of Is of size n, that is I(n) = {(1), (2), . . . , (n)}, where the round
brackets are used to index the elements in I(n). For example, Is could be all potential HLMs
which could be included in an experiment and I(n) a set of HLMs actually selected for the
experiment. We will call the elements of population S subjects. Furthermore, let x ∈ X ⊂ Rt
and let z ∈ Z ⊂ Rq, where t and q are some natural numbers. In general terms, we can write





+ εij(k), i = 1, . . . , rj(k), j = 1, . . . , n(k), (k) ∈ I(n), (1)
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where η is a model function relating the response to the runs of the experiment. In most
applications relevant to the work presented in this paper it is a non-linear function with
respect to both the explanatory variables and the parameters. Furthermore, β(k) denotes a
p-dimensional vector of functions of the covariates z(k) associated with the (k)-th subject,
unknown constant parameters β ∈ Rp1 and a p2-dimensional vector of random effects b(k),
that is, βT(k) =
(
g(k)1(β, b(k), z(k)), . . . , g(k)p(β, b(k), z(k))
)
, where functions g can be linear
or non-linear with respect to both the parameters and the covariates. The total number of




j=1 rj(k). We assume that
b(k) ∼ Np2(0,Σ), ε(k)|b(k) ∼ Nm(k)(0, σ2εI), for all (k) ∈ I(n), (2)
where ε(k) denotes the vector of random errors for subject (k) and m(k) =
∑nk
j=1 rj(k). We
denote by γ a vector of all the model parameters of interest, that is
γ = (βT,σT)T ∈ Rp1+ p2(p2−1)2 × Rp2+1+ , (3)
where βT = (β1, . . . , βp1) and σ is the p3 = {p2 + p2(p2 − 1)/2 + 1}-dimensional vector of
the variances and covariances of the random effects vector b (elements of matrix Σ) and the
error variance, that is σT = (σ21, . . . , σ
2
p2
, σ12, . . . , σp2−1,p2 , σ
2
ε).
2.2 Design and criterion of optimality
Each subject (k) ∈ I(n) is characterized by some covariates z(k). For an efficient experiment
we need to choose subjects, which implies the relevant levels of the covariates, paired with
values of the vector x. In this paper we assume that for a given level (k) the same covariates
are used and we assume that their values do not change with the changes in x. Then, the
experimental design for subject (k) can be written in the following way:
ξ(k) =
 x1(k) . . . xn(k)(k)r1(k) . . . rn(k)(k) ; z(k)
 , (k) ∈ I(n), xj(k) ∈ X , zj(k) ∈ Rq(k) , rj(k) ∈ N.
The replications rj(k) of the support points (z(k), xj(k)) are natural numbers, that is we
consider exact designs. The experiment is performed over a subset I(n) of the available
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subjects of population S and the design for the subset is denoted by ζ =
{
ξ(1), . . . , ξ(n)
}
. We
call ζ a population design, where subjects (k) and values of the explanatory variables x are
the design variables. Each subject chosen for the experiment has its individual plan of the
experiment (individual design) ξ(k). In some cases, all subjects will have the same individual
design. Sometimes we will have groups of subjects having the same individual design. The
theory presented in this paper covers all such cases as long as the subjects are independent.
We are interested in efficient estimation of the model parameters γ as defined in (3) and
we choose the D-criterion for finding optimum designs. We have q covariates available, but
in fact we may be interested in a subset of the covariates only. Two special cases are all q
covariates or a single covariate included in the model.
We denote the information matrix corresponding to model (1) by M (ζ,γ). Then the
criterion of optimality can be written as
ψγ(ζ,γ) = log detM(ζ,γ). (4)









where ` denotes the log-likelihood function for the parameters given the observations. Here,
however, the marginal density function of vector y whose entries are as in (1) does not have a
closed form. To approximate the distribution a Taylor series expansion of the model is often
applied. The resulting linear combination of random variables gives a normal distribution if
the variables are normal.
2.3 Model approximation
Lindstrom and Bates (1990) and Gilberg et al. (1999) use the first order approximation of
the Taylor expansion of the model function η around the fixed parameters and the random
effects at their estimates. They are interested in methods for parameter estimation and they
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assume that there are data available to calculate the required initial estimates. At the design
stage there are no data to hand. Hence, we evaluate the approximation at a prior guess of
the fixed effects and at the assumed expectation of the random effects. In our paper we are
using a point prior, denoted by β0, and we assume that E(b(k)) = 0. That is, we expand the










and approximate the model


































β0. Here the derivatives are evaluated at known values


















l′ = 1, . . . , p, l = 1, . . . , p2. Writing the above in the matrix notation we have

































Then, model (1) including all observations for individual (k) can be written as
y(k) ∼= α(k) + F(k)Z(k)β + F(k)H(k)b(k) + ε(k), (6)
where α(k) is the m(k)-dimensional vector of constants αj(k), each repeated rj(k) times, F(k)
is the (m(k) × p)-dimensional matrix whose rows are fTj(k), each row repeated rj(k) times.
We assume that random vectors b(k) and ε(k) are independent and have multivariate normal
distributions as in (2). Hence, the approximate expectation and the dispersion matrix of







εIm(k) . The distribution of y(k) is approximately normal, that is,
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y(k) ∼
approx
Nm(k)(µ(k),V(k)), where µ(k) depends on the vector of parameters β, while V(k)
depends on the vector of the variances and covariances σ.
2.4 Fisher Information Matrix
The log-likelihood function for the full vector of parameters, given the responses of the (k)-th
subject, approximated by (6), is








































and σi are elements of the p3-dimensional vector σ. We assume that the subjects are
independent. Hence, the information matrix for the whole design, which we will call the
Population Fisher Information Matrix and denote by M , is the sum of the individual
information matrices, M =
∑
(k)∈I(n)M(k) and the D-optimality criterion function is
log detM = log det diag{B,C} = log detB detC = log detB + log detC,
where B =
∑




3.1 Enzyme kinetics model
In a typical enzyme kinetics reaction enzymes bind to substrates and turn them into products.
The binding step is reversible while the catalytic step is irreversible. In chemical notation
S + E ←→ ES → E + P,
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where S, E and P denote substrate, enzyme and product. The reaction rate is represented
by the Michaelis-Menten model v =
Vmaxx
Km + x
, where x is the concentration of the substrate
([S]) and Vmax and Km are the model parameters: Vmax denotes the maximum velocity of
the enzyme and Km is the Michaelis-Menten constant; it is the value of x at which half of
the maximum velocity Vmax is reached.
In our example, Is is the set of all available HLM preparations. We have s = 47 and the
substrate concentration x is assumed to belong to the interval X = [0.3, 50]. Typically, there
would be several concentration levels and each would be used for measuring the response
(the reaction rate) from each HLM. In Figure 1 we present observations for the 47 liver
microsomal preparations of such a standard experiment. We will call this design rich. The
differences among the subjects are clearly seen in the values of parameter Vmax, the horizontal
asymptote of the Michaelis-Menten model.
[Figure 1 about here.]
There are six cytochrome P450 enzymes specific for each HLM, characterized by the enzyme
activities (covariates z, q = 6). Enzyme activity describes the intrinsic ability of an enzyme to
convert one molecule into another and it is related to the substrate concentration (Michaelis-
Menten Kinetics). We model the response function η as the Michaelis-Menten function, where
the parameters may depend on the covariate values of the subjects (HLMs), which is indicated









We observe, based on the data set shown in Figure 1 and the related activities, that the
highest correlation of the enzyme activities with the Michaelis-Menten model parameters
is that of CYP2B6 with the maximum velocity of the enzyme Vmax. Enzyme activity is a
positive continuous variable. For numerical calculations in the example presented in this
work we standardized the natural log of the covariate.
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If we include just one covariate (activity of one enzyme) related to Vmax(k) only, then vector











The dimensions here are p = dim(β(k)) = 2, p1 = dim(β) = 3, p2 = dim(b(k)) = 1 and
p3 = dim(σ) = 2. Also, b(k) ∼ N (0, σ2b ) and γT = (βT,σT) = (β0, β1, β2, σ2b , σ2ε). Matrices





















































These applied to M given in Section 2.4 will give the population FIM for our example.
3.2 Optimal design search algorithm
The typical method of finding optimal designs for moderate to large run sizes is to seek
continuous optimal designs and round them to the run size required. However, in the case
considered here, this is not possible since the optimality criterion is not proportional to
the run size N . This is a feature of mixed models where we are interested in the variance
components. Instead, we search for exact optimal designs under a local design optimality
criterion, for different run sizes, using the Fedorov exchange algorithm.
For each run of the experiment, we must choose an HLM, which implies a choice of a
covariate value and a substrate concentration. Since the substrate concentrations are on
a continuous scale, we reduce the problem by choosing values from a candidate set. In
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practice, this candidate set should be spaced out according to what could be expected to be
practically different concentrations. In the following illustration, we used a discrete subset of
concentrations from the interval [0.3, 50] and the set of 47 HLMs, which were used to obtain
the rich design. We start with a candidate set of treatments which is obtained by all possible
combinations of selected concentration levels and 47 HLMs.
A randomly (with replacement) selected N treatments from the candidate set is considered
as the initial design, which is then updated using the exchange algorithm. To compete with
the initial design, a competing design is obtained by interchanging the first treatment of the
initial design by a treatment of the candidate design. The initial and competing designs are
compared with respect to the design criterion and the competing design is considered as the
current best design (Case I) if it corresponds to a higher design criterion value than that of
the initial design, otherwise, the initial design is considered as the current best design (Case
II). To compete with the current best design, the new competing design is obtained either by
replacing the second treatment (for Case I) or the first treatment of the current best design
(for Case II) with a new treatment of the candidate set. This search procedure is continued
while there is a competing design with higher design criterion value than the current best
design; otherwise, the current best design is considered as the optimal design. For exact
design, there is no guarantee that the exchange algorithm leads to the global optimal design,
so in practice it is preferable to repeat the search procedure for a number of different initial
designs to obtain the optimal design.
3.3 Transformation
The algorithm described above can be run with a standard D-optimality criterion. However,
in practical situations relevant to this work it is often the case that the random errors of
observations are not normally distributed. If this is a possible scenario, we propose to trans-
form the model and adjust the optimality criterion to take into account the transformation
12 Biometrics, 000 0000









+ εij(k), i = 1, . . . , rj(k), j = 1, . . . , n(k), (k) ∈ I(n), (7)





, when λ 6= 0;
log y, when λ = 0.
(8)
Gilberg et al. (1999) compared estimation results for a Michaelis-Menten mixed effects model
which is weighted and/or transformed on both sides by various methods. For their example
the transform both sides models worked better than the non-transformed ones.
The transformation requires adjustments in the linearized model and in the information
matrix. For a given value of λ 6= 0, the derivative of η(λ) with respect to βl is ηλ−1 ∂η∂βl and


























































fTj(k). Then, the linearized
transformed model including all observations for individual (k) has the same form as (6)
with α˜(k) replacing α(k) and F˜(k) replacing F(k), where α˜(k) is the m(k)-dimensional vector
of constants α˜j(k), each repeated rj(k) times, F˜(k) is the (m(k)× p)-dimensional matrix whose




∼= α˜(k) + F˜(k)Z(k)β + F˜(k)H(k)b(k) + ε(k). (10)
This model should be now used to obtain the information matrix M˜ which will have the
same form as before but with the adjusted derivatives to account for the transformation.


























The transformation parameter λ is usually unknown and has to be estimated. This means
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that now we have a multiple objective: efficient estimation of both λ and γ. Since the joint
estimation leads to difficulties with computation and interpretation, to find λ stabilizing the
random errors we use the simple fixed effects model (Latif and Gilmour, 2015)
y
(λ)
ij(k) = τj(k) + δij(k), δij(k) ∼ N (0, σ2δ ). (11)
This can be considered as a simple ANOVA model, with Box-Cox transformation, with
the vector τ of treatment effects τj(k). Optimal design for the ANOVA model with Box-
Cox transformation was considered by Atkinson and Cook (1997) for several design criteria,
including Ds-optimality for estimating the transformation parameter λ, which we adopt here
as part of our compound criterion. We denote by M˜ (ζ, τ , σ2δ , λ) the information matrix for
all the parameters of model (11), that is for the treatment effects, the unknown variance
and the unknown transformation parameter λ. As we are interested in efficient estima-





− log [cTM˜ (ζ, τ , σ2δ , λ)−1c], where cT = (0, 0, . . . , 0, 1) has dimension ∑(k)∈I(n) n(k) + 2.
The compound criterion of design optimality for efficient estimation of both the transfor-
mation parameter λ and the vector of model parameters γ, is then
ψ(ζ,γ, λ) = ψλ(ζ, λ) + ψγ(ζ,γ) = − log
[
cTM˜ (ζ, τ , σ2δ , λ)
−1c
]
+ log detM˜(ζ,γ|λ = λ0)
= log
detM˜ (ζ,γ|λ = λ0)
cTM˜ (ζ, τ , σ2δ , λ)
−1c
= log
det B˜(ζ,β|λ = λ0) det C˜(ζ,σ|λ = λ0)
cTM˜ (ζ, τ , σ2δ , λ)
−1c
= log
det B˜(ζ,β|λ = λ0)√
cTM˜ (ζ, τ , σ2δ , λ)
−1c
+ log
det C˜(ζ,σ|λ = λ0)√




The numerical results presented here are obtained for the model introduced in Section 3.3. It
should be noted that another covariate structure would produce different numerical output.
The surface η(λ) as a function of the concentration and of the covariate (activity of enzyme
2B6, standardized) is shown in Figure 2. We can see that as the covariate value increases so
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does the asymptote of the response, that is the value of the parameter Vmax. The covariate
explains some of the variability in the response.
[Figure 2 about here.]
For the single covariate, we obtained designs for N = 50, 100, 150, 200, 250 and compared
them with the design used for the rich data, which had 2N = 846, being all combinations
of 47 HLMs with the 9 concentrations {0.3125, 0.625, 1.25, 2.5, 5.0, 10.0, 20.0, 40.0, 50.0} each
replicated twice. We used estimates of the parameters obtained from the rich design as prior
values for finding the optimum designs which are V̂max = exp{β̂0 + β̂1z}, β̂0 = −3.155, β̂1 =
0.744, K̂m = exp{β̂2}, β̂2 = 0.5463, σ̂2b = 0.373, σ̂2ε = 0.059. For our optimization we used a
regular grid of concentrations in the region of [0.3, 50] in steps of 0.1 after refining a coarser
grid and the same set of HLMs as in the rich design. The points selected by the algorithm
for N = 50, 100, 150, 200, 250 are shown in Figure 3 together with the rich design points.
[Figure 3 about here.]
Some patterns, with minor variations, are clear. The structure of these optimum designs is
very different from the typical set-up used in practice. Only four concentrations are used,
apart from the design for N = 250 where there is one point chosen at a fifth concentration.
The lowest possible concentration is combined with the HLMs with the lowest covariate
values. The second and third chosen concentration values, close to the prior value assumed
for Km, are combined with several HLMs with the highest values of the covariate. Finally,
the highest possible concentration is used with many HLMs, starting with those at each
extreme and working towards the middle as the run size increases.
The marginal optimal designs shown in Figure 4 indicate the number of replications of the
support points for the values of N considered. Both concentration and the activity values on
the borders of the design region are chosen much more often than the internal points.
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[Figure 4 about here.]
In particular, it is interesting to observe two characteristics of the marginal design for the
choice of covariate values: first, that all the available values are chosen whenN = 100 or more,
and second that the weight is mostly put on the border values. The former characteristic is
related to the fact that the response depends on the covariate z via the parameter Vmax and
the latter is related to the fact that the response depends linearly on Vmax and so the end
points of the parameter region will be most informative.
Note that this shows only the covariate value and does not distinguish between different
HLMs with the same value, some of which existed in the data set used. The designs are given
in full in Tables 1–5 of Appendix B and the original data are given in Appendix A, both
appendices are in the on-line supplementary material.
Furthermore, looking at the marginal design for the concentration values, we see that a
large weight is put on the biggest concentration value, which gives information on the Vmax
parameter, which is considered as random. On the other hand, parameter Km is assumed to
be constant and so only some of the covariate values are combined with the concentrations
which give information on this parameter.
We use a relative efficiency measure for a population design ζ compared with another
design, for example a standard design used in practice. In our case we compare the optimum








where both designs are evaluated at some prior parameter values γ0.
The relative efficiency of the optimal designs obtained for various values of N to the rich
design are shown in Figure 5. We also calculated the relative efficiency for the optimal design
replicated 2, 3, 4 and 5 times.
[Figure 5 about here.]
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We can see that two replications of a 250-point optimal design is as good as the rich design
(which is a 423-point design replicated twice). We could use 500 runs of the experiment
rather than 846 to obtain the same efficiency of estimation if we do the design optimization
including a covariate which explains a significant part of the response variability.
The 50-point design, even when replicated 5 times, is worse than the rich design. This
is because it does not carry enough information on the variable parameter Vmax; not all
available covariate values are combined with the largest value of the concentration. On the
other hand, the 100-point design replicated five times is almost equally efficient as the 250-
point design replicated twice. In fact, in both designs all covariate values are combined with
the largest concentration value. Furthermore, if we could use a similar number of runs as in
the rich design, then for example, the 200-point design replicated four times would give a
higher efficiency, still with slightly fewer runs. Of course, the rich design might have other
advantages, especially in allowing for checking the assumed functional form of the model,
which are not captured by the optimality criterion. However, this was not a major concern
in the application considered here, where the enzyme mechanism is well understood.
The results are based on the linear approximation of the model. For fixed effects models
there are tools to check both the intrinsic and parameter curvatures; c.f., Bates and Watts
(1980). For such models design efficiency criteria have been suggested, as in Hamilton and
Watts (1985). Bogacka and Wright (2004) have compared D-optimality with Hamilton and
Watts’ Quadratic criterion, which incorporates measures of both curvatures. They also
considered a constrained design strategy, where the number of design replications ensures
that the curvature is less than some fixed threshold. As is shown in Bates and Watts (1980)
the curvatures are reduced by a factor of 1/
√
r, where r denotes the replication of the design.
It might therefore be better to use an optimum design with a smaller number of points, but
replicated more times, such as 10 replications of the 50-point optimum design. However, to
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the best of our knowledge, no work has been done regarding the effect of curvature on the
robustness of experimental design for nonlinear mixed effects models with covariates treated
as design variables. This is an important and interesting problem to consider.
We performed 5000 simulations to examine the precision of parameter estimation of the
model using two replications of the 150-, 200-, and 250-point optimum designs, and of the 423-
point rich design, as well as 10 replications of the 50-point optimum design. The estimates
based on the rich data are used as the true values to simulate the response. The results
are reported in Table 1. For each of the estimates, the bias, obtained by subtracting the
true value from the sample mean over the simulations, the sample standard deviation over
the simulations, and the average, over the simulations, of the estimated standard error are
reported.
[Table 1 about here.]
There is not much difference in the precision of estimation, but the rich design gives slightly
smaller bias in estimating the transformation parameter λ. However, the estimated standard
error of λˆ is closer to the simulated standard deviation for the optimal designs compared
with that of the rich design.
The comparison between two replications of the 250-point optimum design and 10 replica-
tions of the 50-point optimum design shows that the latter gives smaller bias of all the fixed
parameters and of the error variance. However, the bias of the variance σ2b of the random
effect is almost twice as big from 10 replicates of the 50-point design as from two replicates
of the 250-point design. This may be indicating some properties of such designs in the case
of models with parameters being functions of covariates and random effects. In our case Vmax
is modelled as a linear function of the enzyme activity and an additive random variable. The
250-point design puts substantial weight on the ends of the design region, as seen in Figure
4(e). In particular, large weights on the end-points of the covariate’s domain as well as the
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use of all covariate values at the end of the concentration’s domain will be important for
estimation of σ2b , a parameter evaluating the population variability due to the covariate.
4. Conclusions
In this paper we present a new method of designing experiments for non-linear mixed effects
models where covariates are design variables combined with an explanatory variable or
another treatment factor. We give forms of the information matrix and of the D-optimality
criterion for such a case and also expanded the criterion to allow for transformation of the
response in case of non-normal random errors.
The theory is exemplified by data on Human Liver Microsomes with various enzyme
activities. Several optimized designs are presented and their properties studied. We observe
that substantial savings can be achieved by using such designs. The new designs can be
equally efficient using less experimental material than is needed in standard practice or, if a
similar experimental effort is allowed, then we can achieve higher efficiency.
Furthermore, using mixed-effects models with covariates we gain information on the popu-
lation variability and are able to asses the variation of the response due to the covariates. This
can be useful for stratification of the population and also for personalizing the treatments.
In this paper we assume that we know which covariate is important for the response and
we chose values of this covariate to optimize the design. More work is needed to further
develop the methodology to optimally choose among several covariates during the stage of
designing experiments.
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Figure 1. Observations of reaction rates for a substrate in 47 HLM preparations. There
are two observations at each of the design points (substrate concentrations).
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Figure 2. The transformed model surface as a function of the concentration and the
normalized log of the covariate fitted to the rich data set.
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(a) N = 50 (b) N = 100




































(c) N = 150 (d) N = 200


















(e) N = 250
Figure 3. Optimum concentration levels and activity values obtained for five different
values of the total number of observations N (grey points indicate rich design).
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(a) N = 50 (b) N = 100
(c) N = 150 (d) N = 200
(e) N = 250
Figure 4. Support points of the optimal designs and the marginal designs (grey dots
indicate rich design). The size of a dot indicates the number of replications of the support
point.
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Figure 5. Relative efficiencies of the optimal designs, and of replicates of these designs,
with respect to the rich design.
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Table 1
Simulation results for comparing two replicates of 150-, 200-, and 250-point optimum designs, 10 replicates of
50-point optimum design and two replicates of 423-point rich design. The results are based on 5,000 simulations and
estimates obtained from the rich data are used as true values.
r ×N β0 β2 β1 σb σ λ
2× 150 bias 0.0044 -0.0005 -0.0009 -0.0083 -0.0076 0.0292
sd 0.0556 0.0320 0.0567 0.0406 0.0057 0.0198
se 0.0556 0.0312 0.0560 0.0174
sd/se 1.0006 1.0246 1.0128 1.1383
2× 200 bias 0.0043 -0.0001 -0.0011 -0.0100 -0.0054 0.0203
sd 0.0556 0.0278 0.0570 0.0410 0.0050 0.0171
se 0.0552 0.0264 0.0554 0.0149
sd/se 1.0076 1.0534 1.0293 1.1462
2× 250 bias 0.0027 -0.0005 -0.0010 -0.0096 -0.0044 0.0163
sd 0.0559 0.0237 0.0560 0.0405 0.0044 0.0150
se 0.0550 0.0233 0.0551 0.0133
sd/se 1.0157 1.0206 1.0152 1.1239
10× 50 bias 0.0000 -0.0001 0.0003 -0.0176 -0.0018 0.0074
sd 0.0746 0.0261 0.0567 0.0530 0.0043 0.0144
se 0.0727 0.0256 0.0552 0.0142
sd/se 1.0254 1.0195 1.0263 1.0156
2× 423 bias 0.0006 0.0002 -0.0005 -0.0102 0.0009 -0.0016
sd 0.0551 0.0223 0.0550 0.0388 0.0072 0.0270
se 0.0543 0.0222 0.0542 0.0193
sd/se 1.0162 1.0073 1.0145 1.3977
Rich data est -3.1547 1.7268 0.7439 0.3730 0.0591 0.2800
se 0.0556 0.0223 0.0555 0.0192
